Purpose: Immune checkpoint inhibitors combined with antiangiogenic agents produce
benefits in the treatment of advanced hepatocellular carcinoma (HCC). We investigated the …

Abstract Background & Aims Atezolizumab plus bevacizumab (Ate/Bev) has demonstrated
efficacy and safety in patients with advanced hepatocellular carcinoma (HCC) in the phase …

Anti–PD-1/PD-L1 therapy, either by anti–PD-1 antibody or anti–PD-L1 antibody, has efficacy
by reinvigorating tumor-infiltrating CD8+ T cells in a subset of patients with cancer, but it has …

CXCR6 is a receptor for the chemokine CXCL16, which exists as a membrane or soluble
form. CXCR6 is a marker for resident memory T (TRM) cells that plays a role in …

The liver is the central metabolic organ of the body, regulating energy and lipid metabolism,
while also having potent immunological functions. Overwhelming the metabolic capacity of …

Hepatocellular carcinoma remains a global health challenge affecting close to 1 million
cases yearly. Liver transplantation provides the best long‐term outcomes for those meeting …

Conclusions: Our work provides the first detailed spatial map of single-cell phenotypes and
multicellular connections in NASH-HCC. We demonstrate that interactions between MDSCs …

Abstract Background & Aims Single-agent anti-PD1 checkpoint inhibitors convey
outstanding clinical benefits in a small fraction (∼ 20%) of patients with advanced …

Background & Aims RNA N 6-methyladenosine (m 6 A) reader protein YTHDF1 has been
implicated in cancer; however, its role in hepatocellular carcinoma (HCC), especially in non …

Introduction: Although immune checkpoint inhibitors (ICIs) have been considered as
promising agents for the treatment of advanced hepatocellular carcinoma (HCC), previous …